The National Institute for Health and Care Excellence (NICE) published technology appraisal guidance in January 2017 that recommends ibrutinib for the treatment of chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation. Ibrutinib is routinely available to National Health Service patients for these indications in line with NICE’s recommendations if a patient’s doctor considers it to be the most appropriate treatment option.
NICE has not been able to make a recommendation on the use of ibrutinib for use in the treatment of other patients with chronic lymphocytic leukaemia because no evidence submission was received from the product’s manufacturer. Ibrutinib is not therefore routinely commissioned for NHS patients for these other indications. NICE will review this decision if the company decides to make an evidence submission.